Bacterial Pneumonia in Feedlot Cattle: Pathogens, Risk Factors, and Treatment Protocols

Introduction

Bacterial pneumonia represents the most economically significant component of the bovine respiratory disease complex (BRDC) in feedlot cattle. The condition arises from a multifactorial interplay between host immunity, environmental stressors, and primary or secondary bacterial invasion of the lower respiratory tract. The three principal bacterial pathogens involved are Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. These organisms colonize the nasopharynx of healthy cattle and, following stress-induced immunosuppression or viral coinfection, translocate to the lungs where they incite fibrinous, suppurative, or necrotizing pneumonia [1, 2]. The disease accounts for substantial morbidity, mortality, and treatment costs in feedlot operations worldwide [3]. This article provides an exhaustive review of the bacterial etiologies, predisposing risk factors, antimicrobial susceptibility trends, and evidence-based treatment protocols for feedlot bacterial pneumonia.

Primary Bacterial Pathogens

Mannheimia haemolytica

M. haemolytica (formerly Pasteurella haemolytica biotype A, serotype 1) is the most frequently isolated bacterium from acute fibrinous pneumonia in feedlot cattle [4]. The organism is a Gram-negative coccobacillus that produces a potent leukotoxin (LktA) belonging to the RTX (repeats in toxin) family. LktA specifically targets ruminant leukocytes and platelets, inducing apoptosis and necrosis of alveolar macrophages and neutrophils [5]. The release of proinflammatory cytokines and lysosomal enzymes from lysed leukocytes amplifies pulmonary inflammation, leading to fibrin deposition, thrombosis, and consolidation of lung parenchyma [6]. M. haemolytica also expresses lipopolysaccharide (LPS) and a polysaccharide capsule that contribute to virulence [7]. Serotype A1 is most commonly associated with clinical disease, although serotypes A2 and A6 are also isolated [8].

Pasteurella multocida

P. multocida is a Gram-negative coccobacillus that is frequently isolated from subacute or chronic cases of BRDC, often as a secondary invader following viral infection [9]. Capsular serogroups A and D are most prevalent in bovine respiratory isolates [10]. The organism produces a dermonecrotic toxin (PMT) that activates intracellular signaling pathways, leading to osteolysis and immune modulation [11]. However, the role of PMT in bovine pneumonia is less clear than in atrophic rhinitis of swine. P. multocida is generally considered less virulent than M. haemolytica, but its high prevalence in feedlot lungs and its ability to form biofilms contribute to persistent infections and treatment failures [12].

Histophilus somni

H. somni (formerly Haemophilus somnus) is a Gram-negative coccobacillus that causes a range of disease manifestations in cattle, including pneumonia, myocarditis, thrombotic meningoencephalitis, and reproductive disorders [13]. In the respiratory tract, H. somni colonizes the upper airways and can invade the lower respiratory tract following stress or viral damage. The organism produces a lipooligosaccharide (LOS) that induces endothelial damage and thrombosis, leading to infarctive pneumonia and systemic vasculitis [14]. H. somni also expresses immunoglobulin-binding proteins and undergoes phase variation to evade host immune responses [15]. Its role in BRDC is often underestimated due to fastidious growth requirements and the need for enriched culture media [16].

Other Bacterial Agents

Other bacteria occasionally isolated from pneumonic feedlot cattle include Trueperella pyogenes, Mycoplasma bovis, Bibersteinia trehalosi, and Fusobacterium necrophorum [17]. M. bovis is particularly important as a cause of chronic, treatment-resistant pneumonia and arthritis, often complicating primary bacterial infections [18]. T. pyogenes is associated with abscessation and chronic suppurative pneumonia [19].

Risk Factors

The development of bacterial pneumonia in feedlot cattle is driven by a combination of host, pathogen, and environmental factors. The most critical risk factors are summarized in Table 1.

Table 1. Major Risk Factors for Bacterial Pneumonia in Feedlot Cattle

Transportation is a well-documented stressor that elevates circulating cortisol and suppresses lymphocyte proliferation, increasing susceptibility to bacterial colonization [20]. Commingling of cattle from multiple sources introduces diverse bacterial and viral strains, overwhelming herd immunity [21]. Viral infections, particularly with BHV-1 and BRSV, damage the respiratory epithelium and impair mucociliary clearance, facilitating bacterial invasion [22]. The role of BVDV in immunosuppression through depletion of lymphoid tissues is also significant [23].

Pathogenesis

The pathogenesis of bacterial pneumonia in feedlot cattle follows a sequential cascade. Initial viral infection or stress-induced immunosuppression allows opportunistic bacteria to proliferate in the nasopharynx. Aspiration of bacteria into the lower airways occurs through microaspiration or inhalation of aerosolized droplets [24]. In the lung, bacterial virulence factors such as LktA, LPS, and LOS trigger an intense inflammatory response. Neutrophils are recruited to the alveoli but are lysed by LktA, releasing proteolytic enzymes and reactive oxygen species that damage lung parenchyma [25]. Fibrinogen leaks from damaged capillaries and is converted to fibrin, resulting in fibrinous pleuritis and consolidation. Thrombosis of pulmonary vessels leads to ischemic necrosis and abscess formation [26]. The resulting clinical signs include fever, depression, anorexia, tachypnea, nasal discharge, and cough. Without intervention, death can occur within 24 to 72 hours [27].

Diagnostic Approaches

Antemortem diagnosis relies on clinical scoring systems (e.g., the DART system: Depression, Appetite, Respiration, Temperature) combined with thoracic auscultation and ultrasonography [28]. Confirmatory diagnostics include:

• Transtracheal wash or bronchoalveolar lavage for cytology and culture.
• Quantitative PCR panels targeting M. haemolytica, P. multocida, H. somni, and M. bovis.
• Antimicrobial susceptibility testing via disk diffusion or broth microdilution.
• Thoracic ultrasound to detect consolidation, abscesses, and pleural effusion.

Postmortem examination reveals cranioventral consolidation, fibrinous pleuritis, and necrotic foci. Histopathology shows fibrinosuppurative bronchopneumonia with alveolar necrosis and thrombosis [29].

Treatment Protocols

Antimicrobial Selection

Treatment of bacterial pneumonia in feedlot cattle requires rapid intervention with antimicrobials that achieve high concentrations in lung tissue and are active against the target pathogens. Commonly used antimicrobial classes include:

• Tetracyclines: Oxytetracycline, chlortetracycline (bacteriostatic, broad-spectrum).
• Fluoroquinolones: Enrofloxacin, danofloxacin (bactericidal, concentration-dependent).
• Macrolides: Tulathromycin, gamithromycin, tilmicosin (bacteriostatic, long half-life).
• Cephalosporins: Ceftiofur (third-generation, bactericidal).
• Phenicols: Florfenicol (bacteriostatic, active against M. haemolytica and P. multocida).

The choice of antimicrobial should be guided by local susceptibility patterns. Table 2 summarizes typical susceptibility profiles.

Table 2. Antimicrobial Susceptibility Trends in Feedlot Bacterial Pathogens

Data compiled from multiple surveillance studies [30, 31, 32].

Metaphylaxis

Metaphylaxis, the mass administration of antimicrobials to high-risk cattle upon arrival at the feedlot, is a widely used strategy to reduce the incidence of BRDC. The decision to implement metaphylaxis is based on risk factors such as body weight, source, transport distance, and commingling history [33]. Commonly used metaphylactic agents include tulathromycin, gamithromycin, and ceftiofur crystalline free acid. Studies have shown that metaphylaxis reduces morbidity by 30-50% and mortality by 20-40% compared to untreated controls [34, 35]. However, concerns about antimicrobial resistance have prompted calls for more judicious use and the development of alternative strategies [36].

Supportive Care

Supportive therapy includes nonsteroidal anti-inflammatory drugs (NSAIDs) such as flunixin meglumine or meloxicam to reduce fever and inflammation. Fluid therapy may be indicated in dehydrated animals. In severe cases, oxygen supplementation and bronchodilators (e.g., clenbuterol) can be considered, though evidence in feedlot cattle is limited [37].

Treatment Failure and Relapse

Treatment failure is common, with reported relapse rates of 10-25% [38]. Causes include:

• Inadequate antimicrobial spectrum or dosing.
• Presence of M. bovis or T. pyogenes which are intrinsically resistant to many beta-lactams.
• Pulmonary abscessation or sequestra that prevent drug penetration.
• Antimicrobial resistance, particularly to tetracyclines and macrolides [39].

When relapse occurs, a second-line antimicrobial from a different class should be selected based on culture and sensitivity results.

Antimicrobial Resistance Trends

Antimicrobial resistance (AMR) in feedlot bacterial pathogens is a growing concern. Resistance to tetracyclines is widespread, with over 40% of M. haemolytica isolates showing resistance in some regions [40]. Macrolide resistance, mediated by erm(42) and msr(E) genes, has been reported in M. haemolytica and P. multocida [41]. Fluoroquinolone resistance remains low (<5%) but has been documented [42]. The use of metaphylaxis has been associated with increased selection for resistant strains [43]. Surveillance programs such as the National Antimicrobial Resistance Monitoring System (NARMS) in the United States and the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) provide ongoing data [44].

Prevention and Control

Prevention of bacterial pneumonia relies on reducing stress and enhancing immunity. Key strategies include:

• Vaccination: Modified-live or killed vaccines against M. haemolytica (leukotoxin toxoid), P. multocida, and H. somni are available. Efficacy is variable, but multivalent vaccines administered prior to shipping can reduce BRDC incidence [45].
• Management: Minimizing transport time, providing clean water and feed upon arrival, and avoiding overcrowding.
• Nutritional support: Adequate levels of trace minerals (zinc, copper, selenium) and vitamins (A, E) support immune function [46].
• Biosecurity: All-in/all-out management, isolation of sick animals, and proper ventilation.

The decision algorithm for metaphylaxis and treatment is illustrated in Figure 1.

flowchart TD
    A[Arrival of feedlot cattle], > B{Risk assessment}
    B, >|High risk| C[Administer metaphylaxis]
    B, >|Low risk| D[Monitor daily for clinical signs]
    C, > D
    D, > E{Clinical signs of pneumonia?}
    E, >|No| F[Continue monitoring]
    E, >|Yes| G[Clinical examination and scoring]
    G, > H[Antimicrobial therapy based on protocol]
    H, > I{Response within 48-72 hours?}
    I, >|Yes| J[Complete course, re-evaluate]
    I, >|No| K[Perform diagnostic sampling: culture, PCR, susceptibility]
    K, > L[Adjust antimicrobial based on results]
    L, > M[Consider supportive care and NSAIDs]
    M, > N{Relapse or chronic case?}
    N, >|Yes| O[Second-line therapy, consider M. bovis involvement]
    N, >|No| P[Recovery and return to pen]

Conclusion

Bacterial pneumonia in feedlot cattle remains a major challenge for the beef industry. The primary pathogens M. haemolytica, P. multocida, and H. somni are well characterized, but their interactions with host immunity and viral cofactors are complex. Effective control requires a multifaceted approach including risk-based metaphylaxis, judicious antimicrobial use guided by susceptibility testing, and improved management practices to reduce stress. The emergence of antimicrobial resistance underscores the need for ongoing surveillance and the development of alternative therapies such as bacteriophages, immunomodulators, and novel vaccines. Future research should focus on host genetics, the microbiome of the respiratory tract, and precision medicine approaches to tailor treatment to individual animals or cohorts.

References

[1] Griffin D. Economic impact associated with respiratory disease in beef cattle. Vet Clin North Am Food Anim Pract. 1997;13(3):367-377.

[2] Mosier DA. Bacterial pneumonia. Vet Clin North Am Food Anim Pract. 1997;13(3):483-493.

[3] Snowder GD, Van Vleck LD, Cundiff LV, Bennett GL. Influence of breed, heterozygosity, and disease incidence on estimates of variance components of respiratory disease in preweaned beef calves. J Anim Sci. 2005;83(6):1247-1261.

[4] Rice JA, Carrasco-Medina L, Hodgins DC, Shewen PE. Mannheimia haemolytica and bovine respiratory disease. Anim Health Res Rev. 2007;8(2):117-128.

[5] Highlander SK. Molecular genetic analysis of virulence in Mannheimia (Pasteurella) haemolytica. Front Biosci. 2001;6:D1128-D1150.

[6] Czuprynski CJ, Leite F, Sylte M, et al. Complexities of the pathogenesis of Mannheimia haemolytica infections: a review. Anim Health Res Rev. 2004;5(2):277-282.

[7] Lo RY. Genetic analysis of virulence factors of Mannheimia haemolytica A1. Vet Microbiol. 2001;83(3):193-207.

[8] Klima CL, Zaheer R, Cook SR, et al. Pathogens of bovine respiratory disease in North American feedlots: a review. Anim Health Res Rev. 2014;15(2):139-150.

[9] Dabo SM, Taylor JD, Confer AW. Pasteurella multocida and bovine respiratory disease. Anim Health Res Rev. 2007;8(2):129-150.

[10] Harper M, Boyce JD, Adler B. Pasteurella multocida pathogenesis: 125 years after Pasteur. FEMS Microbiol Lett. 2006;265(1):1-10.

[11] Wilson BA, Ho M. Pasteurella multocida: from zoonosis to cellular microbiology. Clin Microbiol Rev. 2013;26(3):631-655.

[12] Boukahil I, Czuprynski CJ. Mannheimia haemolytica biofilm formation on bovine respiratory epithelial cells. Vet Microbiol. 2016;197:45-51.

[13] Corbeil LB. Histophilus somni host-parasite relationships. Anim Health Res Rev. 2007;8(2):151-160.

[14] Inzana TJ, Balyan R, Howard MD. Characterization of a lipooligosaccharide from Histophilus somni. Infect Immun. 1997;65(11):4675-4681.

[15] Sandal I, Inzana TJ. A genomic window into the virulence of Histophilus somni. Trends Microbiol. 2010;18(2):90-98.

[16] O'Toole D, Sondgeroth KS, Sondgeroth KS, et al. Histophilus somni myocarditis in feedlot cattle. J Vet Diagn Invest. 2009;21(5):681-686.

[17] Gagea MI, Bateman KG, van Dreumel T, et al. Diseases and pathogens associated with mortality in Ontario beef feedlots. J Vet Diagn Invest. 2006;18(1):18-28.

[18] Nicholas RA, Ayling RD. Mycoplasma bovis: disease, diagnosis, and control. Res Vet Sci. 2003;74(2):105-112.

[19] Billington SJ, Jost BH, Songer JG. The pathogenic potential of Trueperella pyogenes. Vet Microbiol. 2002;89(4):287-296.

[20] Chirase NK, Greene LW, Purdy CW, et al. Effect of transport stress on respiratory disease, serum cortisol, and immune responses in feeder calves. Am J Vet Res. 2004;65(4):486-492.

[21] Taylor JD, Fulton RW, Lehenbauer TW, et al. The epidemiology of bovine respiratory disease: what is the evidence for predisposing factors? Can Vet J. 2010;51(10):1095-1102.

[22] Ellis JA. The immunology of the bovine respiratory disease complex. Vet Clin North Am Food Anim Pract. 2001;17(3):535-550.

[23] Chase CC, Elmowalid G, Yousif AA. The immune response to bovine viral diarrhea virus: a review. Vet Clin North Am Food Anim Pract. 2004;20(1):1-18.

[24] Ackermann MR, Brogden KA. Response of the ruminant respiratory tract to Mannheimia haemolytica. Microbes Infect. 2000;2(9):1079-1088.

[25] Slocombe RF, Malark J, Ingersoll R, et al. Importance of neutrophils in the pathogenesis of acute pneumonic pasteurellosis in calves. Am J Vet Res. 1985;46(11):2253-2258.

[26] Panciera RJ, Confer AW. Pathogenesis and pathology of bovine pneumonia. Vet Clin North Am Food Anim Pract. 2010;26(2):191-214.

[27] Booker CW, Abutarbush SM, Morley PS, et al. Microbiological and histopathological findings in cases of fatal bovine respiratory disease in feedlot cattle. Can Vet J. 2008;49(3):273-281.

[28] Buczinski S, Forté G, Francoz D, Bélanger AM. Comparison of thoracic auscultation, clinical score, and ultrasonography as indicators of bovine respiratory disease in preweaned dairy calves. J Vet Intern Med. 2014;28(1):234-242.

[29] Caswell JL, Williams KJ. Respiratory system. In: Maxie MG, ed. Jubb, Kennedy, and Palmer's Pathology of Domestic Animals. 6th ed. Elsevier; 2016:465-591.

[30] Portis E, Lindeman C, Johansen L, Stoltman G. A ten-year (2000-2009) study of antimicrobial susceptibility of bacteria that cause bovine respiratory disease complex, Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni, in the United States and Canada. J Vet Diagn Invest. 2012;24(5):932-944.

[31] Lubbers BV, Hanzlicek GA. Antimicrobial multidrug resistance and coresistance patterns of Mannheimia haemolytica isolated from bovine respiratory disease cases, a three-year (2009-2011) retrospective analysis. J Vet Diagn Invest. 2013;25(3):413-417.

[32] DeDonder KD, Apley MD, Li M, et al. Pharmacokinetics and pharmacodynamics of gamithromycin in pulmonary epithelial lining fluid in naturally occurring bovine respiratory disease. J Vet Pharmacol Ther. 2016;39(2):157-165.

[33] Nickell JS, White BJ. Metaphylactic antimicrobial therapy for bovine respiratory disease in stocker and feedlot cattle. Vet Clin North Am Food Anim Pract. 2010;26(2):285-301.

[34] Van Donkersgoed J. Meta-analysis of field trials of antimicrobial mass medication for prophylaxis of bovine respiratory disease in feedlot cattle. Can Vet J. 1992;33(12):786-795.

[35] Abell CE, Theurer ME, Larson RL, White BJ. A mixed treatment comparison meta-analysis of metaphylaxis treatments for bovine respiratory disease in beef cattle. J Anim Sci. 2017;95(2):626-635.

[36] Cameron A, McAllister TA. Antimicrobial usage and resistance in beef production. J Anim Sci Biotechnol. 2016;7:68.

[37] Fajt VR, Apley MD, Roth JA, et al. The effects of danofloxacin and tilmicosin on neutrophil function and lung consolidation in calves with experimentally induced Mannheimia haemolytica pneumonia. J Vet Pharmacol Ther. 2003;26(4):269-276.

[38] Booker CW, Jim GK, Guichon PT, et al. Evaluation of the efficacy of tulathromycin as a metaphylactic antimicrobial in feedlot calves. Can Vet J. 2007;48(2):159-164.

[39] Klima CL, Zaheer R, Cook SR, et al. Antimicrobial resistance in Mannheimia haemolytica and Pasteurella multocida from bovine respiratory disease cases in Alberta, Canada. Can J Vet Res. 2011;75(4):267-274.

[40] Watts JL, Sweeney MT, Lubbers BV. Antimicrobial susceptibility of bacterial pathogens from bovine respiratory disease: 2011-2012. J Vet Diagn Invest. 2014;26(6):789-794.

[41] Desmolaize B, Rose S, Warrass R, Douthwaite S. A novel Erm monomethyltransferase in antibiotic-resistant isolates of Mannheimia haemolytica and Pasteurella multocida. Mol Microbiol. 2011;80(1):184-194.

[42] Michael GB, Freitag C, Wendlandt S, et al. Emerging issues in antimicrobial resistance of bacteria from food-producing animals. Future Microbiol. 2015;10(3):427-443.

[43] Checkley SL, Campbell JR, Chirino-Trejo M, Janzen ED. Antimicrobial resistance in Mannheimia haemolytica and Pasteurella multocida isolated from beef feedlot cattle in Alberta. Can Vet J. 2008;49(5):473-477.

[44] United States Department of Agriculture. NARMS 2019 Integrated Report. USDA; 2021.

[45] Larson RL, Step DL. Evidence-based effectiveness of vaccination against Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in feedlot cattle. Vet Clin North Am Food Anim Pract. 2012;28(1):97-106.

[46] Galyean ML, Perino LJ, Duff GC. Interaction of cattle health/immunity and nutrition. J Anim Sci. 1999;77(5):1120-1134.

[47] Confer AW, Ayalew S. Mannheimia haemolytica in bovine respiratory disease: immunogens, potential immunogens, and vaccines. Anim Health Res Rev. 2018;19(1):79-99.

[48] Fulton RW, Confer AW. Bovine respiratory disease complex: a review of the role of viruses and bacteria. Vet Clin North Am Food Anim Pract. 2012;28(1):1-16.

[49] Gorden PJ, Kleinhenz MD, Ydstie JA, et al. Efficacy of tulathromycin and florfenicol for the treatment of bovine respiratory disease in high-risk feedlot calves. J Anim Sci. 2013;91(7):3427-3435.

[50] Woolums AR, Loneragan GH, Hawkins LL, Williams SM. Baseline management practices and health outcomes in U.S. feedlots: a review. J Anim Sci. 2005;83(E Suppl):E15-E24.